{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-008682","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.510496+00:00","generated_at":"2026-05-22T16:26:07.434586+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"GT Biopharma appoints Michael Breen as CEO, effective April 29, 2025","bullets":["Michael Breen appointed CEO for a two-year term; he had served as Interim CEO since March 2022.","Breen continues as Executive Chairman and Board member, roles held since January and November 2021.","Breen is a UK-qualified solicitor and former senior partner at Clyde & Co., advising biotech clients.","No compensatory terms or changes to existing arrangements disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-008682","json":"https://secwatch.observer/filing/0001641172-25-008682.json","markdown":"https://secwatch.observer/filing/0001641172-25-008682.md","text":"https://secwatch.observer/filing/0001641172-25-008682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000164117225008682/0001641172-25-008682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000164117225008682/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:26:07.434586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59b2ab6a35","claim":"Michael Breen was appointed as Chief Executive Officer at GT Biopharma, Inc..","evidence_excerpt":"On April 29, 2025, GT Biopharma, Inc. (the “Company”) appointed Michael Breen as its Chief Executive Officer for a two-year term, effective as of April 29, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000164117225008682/0001641172-25-008682-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}